Details

Autor(en) / Beteiligte

• WELLER, Michael
• BERGER, Hilmar
• LOEFFLER, Markus
• PIETSCH, Torsten
• VON DEIMLING, Andreas
• HARTMANN, Christian
• SCHRAMM, Johannes
• WESTPHAL, Manfred
• SIMON, Matthias
• GOLDBRUNNER, Roland
• KREX, Dietmar
• STEINBACH, Joachim P
• OSTERTAG, Christoph B

Titel

Combined 1p/19q Loss in Oligodendroglial Tumors: Predictive or Prognostic Biomarker?

Ist Teil von

• Clinical cancer research, 2007-12, Vol.13 (23), p.6933-6937

Ort / Verlag

Philadelphia, PA: American Association for Cancer Research

Erscheinungsjahr

2007

Link zum Volltext

Quelle

MEDLINE

Beschreibungen/Notizen

• Purpose: The combined loss of genetic material on chromosomes 1p and 19q is strongly associated with favorable outcome in patients with WHO grade 3 anaplastic oligodendroglial tumors. The prognostic value of 1p/19q loss in WHO grade 2 oligodendroglial tumors is less well defined. Importantly, the possible effect of combined 1p/19q loss has not been studied in patients who were not treated with radiotherapy or chemotherapy. Experimental Design: Seventy-six patients with oligodendroglioma ( n = 33), oligoastrocytoma ( n = 30), anaplastic oligodendroglioma ( n = 6), or anaplastic oligoastrocytoma ( n = 7) were identified who had not received radiotherapy or chemotherapy after their first operation until the end of follow-up or until the first progression and had tissue for 1p/19q status available. 1p/19q status was assessed by multiplex ligation–dependent probe amplification. Results: After a median follow-up of 3.8 years, progressive disease was documented in 34 patients. The estimated median progression-free survival was 4.6 years. Fifty-eight of the 76 patients had a combined loss of 1p and 19q. The absence or presence of combined 1p/19q loss was not prognostic for progression-free survival using multivariate adjustment for histology, extent of resection, and gender. Conclusions: Combined 1p/19q loss is not a sensitive prognostic biomarker in patients with oligodendroglial tumors who do not receive radiotherapy or chemotherapy. The gene products lost as a consequence of this codeletion may include mediators of resistance to genotoxic therapies. Alternatively, 1p/19q loss might be an early oncogenic lesion promoting the formation of glial neoplasms, which retain high sensitivity to genotoxic stress.